失智症治療市場：依藥物類別、適應症、給藥途徑、通路和地區分類

據估計，2026年失智症治療市值為279.7億美元，預計2033年將達到449.1億美元。預計從2026年到2033年，該市場將以7.0%的複合年成長率成長。

全球性阿茲海默症和其他失智症病例的不斷增加，推動了失智症治療市場的成長。失智症是由影響大腦的疾病（例如阿茲海默症和中風）引起的綜合症。其特徵是認知功能（例如思考、記憶和推理能力）逐漸衰退。隨著人們對失智症診斷的認知不斷提高，以及治療方法的日益增多，越來越多的人開始尋求醫療協助以應對失智症的症狀。許多藥廠正在大力投資研發能夠延緩或阻止失智症進展的有效藥物。

市場動態

全球人口老化加劇了神經退化性疾病的風險，這主要推動了失智症治療市場的成長。開發中國家醫療保健支出的增加以及生物製藥公司積極的研發活動也進一步促進了市場擴張。然而，市場仍面臨許多挑戰，特別是許多候選藥物在後期臨床試驗中失敗，以及由於這些疾病的複雜性而導致的高昂藥物研發成本。近期核准的緩解疾病藥物旨在作用於疾病的發病機製而非僅僅緩解症狀，這為製藥公司帶來了巨大的機會。政府對失智症研究的支持和資助不斷增加，鼓勵市場參與企業進行創新並開發新的治療方法。隨著人口結構變化導致失智症盛行率持續上升，對有效治療方法的需求預計將會擴大，市場有望取得顯著進展。

本研究的關鍵特徵

本報告對全球失智症治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模和複合年成長率。

本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。

此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。

本研究根據以下參數對全球失智症治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。

本調查涵蓋的主要公司包括 Biogen、 Eisai, Ltd.、Novartis AG、Cipla、H. Lundbeck A/S、Otsuka Pharmaceutical Co., Ltd.、Sun Pharmaceutical Industries Ltd.、Beatrice Company、Mapi Pharma、AbbVie、Daiichi Sank Co., Ltd. 和 F.Abbmann。

本報告中的見解將使各公司的行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。

全球失智症治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。

透過分析全球失智症治療市場中使用的各種策略矩陣，相關人員可能更容易做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 流行病學
• 管道分析

第4章：失智症治療市場：依藥物類別分類，2021-2033年

• 單胺氧化酶抑制劑
• 膽鹼酯酶抑制劑
• 麩胺酸抑制劑
• 其他

第5章：失智症治療市場：依適應症分類，2021-2033年

• 老年失智症失智症
• 路易氏體失智症
• 帕金森氏症和失智症
• 其他

第6章：失智症治療市場：依給藥途徑分類，2021-2033年

• 口服
• 靜脈
• 其他

第7章：失智症治療市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第8章：失智症治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第9章 競爭情勢

• Biogen
• Eisai Co., Ltd.
• Novartis AG
• Cipla
• Lundbeck A/S
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mapi-Pharma Ltd.
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• F.Hoffmann-La Roche Ltd

第10章 分析師建議

• 機會分析
• 一致的機會地圖

第11章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Dementia Drugs Market is estimated to be valued at USD 27.97 Bn in 2026 and is expected to reach USD 44.91 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2019 - 2033)
• MAO Inhibitors
• Cholinesterase Inhibitors
• Glutamate Inhibitor
• Others
• By Indication Insights (Revenue, USD Bn, 2019 - 2033)
• Alzheimer's Disease Dementia
• Lewy Body Dementia
• Parkinson Disease Dementia
• Others
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2033)
• Oral
• Intravenous
• Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Biogen
• Eisai Co., Ltd.
• Novartis AG
• Cipla
• Lundbeck A/S
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mapi-Pharma Ltd.
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• Hoffmann-La Roche Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Dementia Drugs Market, By Drug Class
  • Dementia Drugs Market, By Indication
  • Dementia Drugs Market, By Route of Administration
  • Dementia Drugs Market, By Distribution Channel
  • Dementia Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Dementia Drugs Market, By Drug Class, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• MAO Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Glutamate Inhibitor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Dementia Drugs Market, By Indication, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Alzheimer's Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Lewy Body Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Parkinson Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Dementia Drugs Market, By Region, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mapi-Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• DAIICHI SANKYO COMPANY, LIMITED.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F.Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us